Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | PDE5A | O76074 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9838429 | 0.88 | PDE4B (0.58) | PDE4BKMT2APDE5A | |
| SCHEMBL12354712 | 0.86 | PDE4B (0.68) | PDE4BKMT2APDE5AMEN1MAPT | |
| SCHEMBL10962807 | 0.86 | PDE4B (0.56) | PDE4BKMT2APDE5AMEN1MAPT | |
| SCHEMBL2528129 | 0.86 | PDE4B (0.63) | PDE4BKMT2AMEN1NR3C1 | |
| SCHEMBL2626726 | 0.85 | SMN1; SMN2 (0.61) | PDE4BKMT2AMEN1MAPTNR3C1 | |
| SCHEMBL7012617 | 0.85 | PDE4B (0.67) | PDE4BKMT2APDE5AMEN1MAPT | |
| SCHEMBL31133246 | 0.85 | SMN1; SMN2 (0.61) | PDE4BKMT2AMEN1MAPTNR3C1 | |
| SCHEMBL17963376 | 0.85 | NR3C1 (0.61) | PDE4BKMT2APDE5AMEN1MAPT | |
| SCHEMBL8228061 | 0.84 | PDE4B (0.65) | PDE4BKMT2APDE5AMEN1MAPT | |
| SCHEMBL2772405 | 0.84 | PDE4B (0.65) | PDE4BKMT2APDE5AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902710-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2018-02-27 | — | — | US | disclosed |
| US-9902710-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2016-09-15 | — | — | US | disclosed |
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2016-09-15 | — | — | US | disclosed |
| EP-2560974-B1 | PYRRAZOLOPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-01-27 | — | — | EP | disclosed |
| US-9200016-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200016-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-1113796-A4 | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL MYERS SQUIBB CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6326379-B1 | ERECTILE DYSFUNCTION; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. | 2001-12-04 | — | — | US | disclosed |
| EP-1113796-A1 | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015222-A1 | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
| US-4061632-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4012373-A | ANTIINFLAMMATORY, CNS DEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1977-03-15 | — | — | US | disclosed |
| US-4000277-A | 3,11-Dihydro- 6H-pyrazolo[1,5-a]pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-6-one and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1976-12-28 | — | — | US | disclosed |
| US-3983128-A | CNS DEPRESSANTS, ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-09-28 | — | — | US | disclosed |
| US-3979399-A | ATARACTIC, ANALGESIC, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-09-07 | — | — | US | disclosed |
| US-3966746-A | ATARACTIC, ANALGESIC, HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE9A, PDE10A, PDE6A | PDE4B 15/4885KMT2A 2096/4885PDE5A 6/4885 |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE9A, PDE10A, PDE6A | PDE4B 15/4885KMT2A 2096/4885PDE5A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.